Market Dynamics of Heparin Market

Key Drivers for Heparin Market

• Increasing Prevalence of Cardiovascular Diseases is inflating the heparin market.

Chronic blood diseases cases are increasing exponentially and are expected to propel the global antiplatelet drugs market. Chronic disease prevalence increase is due to drive the market. The increase in the incidence of cardiovascular diseases is one of the key drivers of the growth rate of the antiplatelet drugs market. Cardiovascular disease is the leading cause of mortality in both developed and developing economies.

It is estimated by the Centers for Disease Control and Prevention (CDC) that more than 8,00,000 people in the United States pass away every year due to stroke and other cardiovascular diseases.
For instance, a World Health Organization (WHO) study has reported that cardiovascular diseases (CVDs) are responsible for approximately 31% of total patient deaths every year.
For instance, in 2022, as noted in a National Library of Medicine study, cardiovascular diseases (CVD) were responsible for approximately 19.8 million deaths globally, necessitating the effective treatment of heparin in controlling thrombosis and mitigating mortality rates of CVD-related complications.
The increasing rate of CVDs is a major factor behind the need for heparin:
Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a major cause of cardiovascular mortality worldwide. VTE risk doubles every decade after the age of 40, and is also very high among inpatients, with the incidence of 10 to 20 cases per 1,000 admissions.
Atrial fibrillation, a prevalent cardiac arrhythmia, occurs in an estimated 12.1 million Americans by 2030, and this boosts the demand for anticoagulant drugs such as heparin.
These highlights the imperative function of heparin in treating and preventing cardiovascular disease-related complications, thus fueling market expansion.

• Rising number of geriatric populations increases CVD which in turn increases the usage of heparin and the market is expanding.

Growing geriatric population globally is expected to support heparin drugs demand since this group is susceptible to heart diseases. The population of individuals over 65 years is expected to double in the future years. The old-aged individuals are susceptible to many chronic diseases like cardiovascular diseases, which can encourage the demand for heparin drugs globally. There were approximately 382 million aged people, aged 60 years and older, in the world in 2017 and it is projected to grow to 2.1 billion by 2050, as per the United Nations.
Older adults with cardiovascular disease (CVD) often face the challenge of managing multiple chronic or multimorbid conditions, leading to a significant drug burden that complicates their treatment. With the prevalence of multimorbidity ranging from 30% to 83% in individuals aged 65 and older, cardiovascular comorbidities are frequently reported as the most common combination of chronic diseases. This situation is further exacerbated by issues such as functional decline and complex geriatric syndromes (GSs), which are major concerns in the management of this population.
Notably, polypharmacy, defined as the simultaneous use of five or more medications, affects 26.3% to 40% of older adults, with excessive polypharmacy impacting around 10%. The incidence of polypharmacy can reach alarming rates, with studies indicating a 53% to 87% incidence over three years. The presence of geriatric syndromes, which can affect 10% to 60% of older adults, significantly contributes to declines in functional status and quality of life, increased hospital admissions, and higher mortality rates. Additionally, frailty, characterized by a reduced physiological reserve and increased vulnerability to stressors, affects 10% of older adults, with rates as high as 60% in those with severe coronary artery disease. Recognizing these complexities, current CVD management strategies are evolving to better address the specific health needs of older adults. Therefore, it is crucial to establish guidelines for managing older patients with CVD, considering the interplay of multimorbidity, polypharmacy, geriatric syndromes, and frailty.

Key Restraints for Heparin Market

• Raw material shortage and animal-derived product safety issues to hold back the market growth

A significant limitation for these products is the accessibility of raw materials. The majority of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are derived from porcine mucosa, which is sourced exclusively from the pork industry. China stands as the largest producer in the pork sector, providing a substantial supply of raw materials for the production of these heparins. However, recent outbreaks of African Swine Fever (ASF) in China have necessitated the culling of pig populations to manage the disease. Multiple outbreaks of ASF have been reported in China, resulting in a diminished availability of raw materials. For instance, in July 2020, an official from China's Ministry of Agriculture indicated that efforts to control African swine fever were complicated by over 11 confirmed outbreaks and the emergence of new variants, particularly in northern regions of China. 
Additionally, the 2022 report from the European Animal Disease Information System (ADIS) documented 81 ASF outbreaks among domestic pigs in Europe, underscoring the ongoing spread of ASF across various countries and its detrimental impact on pig production systems, animal health, and welfare. 
Overall, safety concerns and the scarcity of raw materials are hindering the growth of the heparin market.

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Global Heparin Market is witnessing significant growth in the near future.

In 2023, the Unfractionated Heparin (UFH) segment accounted for noticeable share of global Heparin Market and is projected to experience significant growth in the near future.

The Deep Vein Thrombosis (DVT) segment is expected to expand at the significant CAGR retaining position throughout the forecast period.

Some of the key companies F. Hoffmann-La Roche Ltd. , Teva Pharmaceutical Industries Ltd. and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.

Frequently Asked Questions